References
1. Institute of Medicine. Clinical Practice Guidelines We Can Trust.
Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, editors.
Washington, DC: The National Academies Press; 2011. 290 p.
2. Campsall P, Colizza K, Straus S, Stelfox HT. Financial Relationships
between Organizations That Produce Clinical Practice Guidelines and the
Biomedical Industry: A Cross-Sectional Study. PLoS Med.
2016;13(5):e1002029.
3. Cosgrove L, Bursztajn HJ, Erlich DR, Wheeler EE, Shaughnessy AF.
Conflicts of interest and the quality of recommendations in clinical
guidelines. J Eval Clin Pract. 2013;19(4):674-81.
4. Johnson L, Stricker RB. Attorney General forces Infectious Diseases
Society of America to redo Lyme guidelines due to flawed development
process. J Med Ethics. 2009;35(5):283-8.
5. Steinbrook R. Guidance for guidelines. N Engl J Med.
2007;356(4):331-3.
6. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP, Guideline Panel
Review Working G. Ensuring the integrity of clinical practice
guidelines: a tool for protecting patients. BMJ. 2013;347:f5535.
7. Schunemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp
IB, et al. Guidelines International Network: Principles for Disclosure
of Interests and Management of Conflicts in Guidelines. Ann Intern Med.
2015;163(7):548-53.
8. Traversy G, Barnieh L, Akl EA, Allan GM, Brouwers M, Ganache I, et
al. Managing conflicts of interest in the development of health
guidelines. CMAJ. 2021;193(2):E49-E54.
9. Shigeta H, Murayama A, Kamamoto S, Saito H, Ozaki A. Evaluation of
Financial Conflicts of Interest and Quality of Evidence Underlying the
American Diabetes Association Clinical Practice Guidelines: The
Standards of Medical Care in Diabetes, 2021. Cureus. 2023;15(3):e36567.
10. Mamada H, Murayama A, Kamamoto S, Kaneda Y, Yoshida M, Sugiura S, et
al. Evaluation of Financial and Nonfinancial Conflicts of Interest and
Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice
Guidelines: Analysis of Personal Payments From Pharmaceutical Companies
and Authors’ Self-Citation Rate in Japan and the United States.
Arthritis Care Res (Hoboken). 2023;75(6):1278-86.
11. Murayama A, Yamada K, Yoshida M, Kaneda Y, Saito H, Sawano T, et al.
Evaluation of Conflicts of Interest among Participants of the Japanese
Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol.
2022;17(6):819-26.
12. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T.
Financial and Intellectual Conflicts of Interest Among Japanese Clinical
Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck
Surg. 2022;166(5):869-76.
13. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery
P, et al. Treating rheumatoid arthritis to target: 2014 update of the
recommendations of an international task force. Annals of the Rheumatic
Diseases. 2016;75(1):3.
14. Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic
and musculoskeletal diseases — past, present and future. Nature
Reviews Rheumatology. 2017;13(7):443-8.
15. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in
Industry Payments to Rheumatologists in the United States During the
COVID-19 Pandemic Between 2013 and 2021. J Rheumatol. 2023;50(4):575-7.
16. Murayama A, Mamada H, Shigeta H, Yoshinaga T, Saito H, Yamashita E,
et al. Financial Relationships Between Pharmaceutical Companies and
Rheumatologists in Japan Between 2016 and 2019. J Clin Rheumatol.
2023;29(3):118-25.
17. Putman MS, Goldsher JE, Crowson CS, Duarte-Garcia A. Industry
Payments to Practicing US Rheumatologists, 2014-2019. Arthritis
Rheumatol. 2021;73(11):2138-44.
18. Murayama A, Ozaki A, Saito H, Sawano T, Shimada Y, Yamamoto K, et
al. Pharmaceutical company payments to dermatology Clinical Practice
Guideline authors in Japan. PLoS One. 2020;15(10):e0239610.
19. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of
interest between pharmaceutical companies and executive board members of
internal medicine subspecialty societies in Japan between 2016 and 2020.
J Eval Clin Pract. 2023;29(6):883-6.
20. Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto
T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to
Japanese board-certified gastroenterologists between 2016 and 2019. BMJ
Open. 2023;13(4):e068237.
21. Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to
Japanese board-certified dermatologists: a 4-year retrospective analysis
of personal payments from pharmaceutical companies between 2016 and
2019. Sci Rep. 2023;13(1):7425.
22. Medical Governance Research Institute. Yen For Docs [Online
database]. Medical Governance Research Institute; 2023 [updated
September 11, 2023. Available from:https://yenfordocs.jp/.
23. Murayama A, Kamamoto S, Murata N, Yamasaki R, Yamada K, Yamashita E,
et al. Evaluation of financial conflicts of interest and quality of
evidence in Japanese gastroenterology clinical practice guidelines. J
Gastroenterol Hepatol. 2023;38(4):565-73.
24. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A.
Evaluation of financial conflicts of interest and drug statements in the
coronavirus disease 2019 clinical practice guideline in Japan. Clin
Microbiol Infect. 2022;28(3):460-2.
25. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T.
Financial conflicts of interest between pharmaceutical companies and the
authors of urology clinical practice guidelines in Japan. Int Urogynecol
J. 2021;32(2):443-51.
26. Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, et al.
Financial payments made by pharmaceutical companies to the authors of
Japanese hematology clinical practice guidelines between 2016 and 2017.
Health Policy. 2021;125(3):320-6.
27. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T.
Pharmaceutical company payments to authors of the Japanese Clinical
Practice Guidelines for Hepatitis C treatment. Liver Int.
2021;41(3):464-9.
28. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T,
Akihiko O. Undisclosed financial conflicts of interest with
pharmaceutical companies among the authors of the Esophageal Cancer
Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus.
2022;35(10).
29. Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Letter to the
editor: Are clinical practice guidelines for hepatitis C by the American
Association for the Study of Liver Diseases and Infectious Diseases
Society of America evidence based? Financial conflicts of interest and
assessment of quality of evidence and strength of recommendations.
Hepatology. 2022;75(4):1052-4.
30. Brems JH, Davis AE, Clayton EW. Analysis of conflict of interest
policies among organizations producing clinical practice guidelines.
PLOS ONE. 2021;16(4):e0249267.
Table 1. Demographic characteristics of clinical practice guideline
authors for rheumatologic arthritis inJapan